NEUROCRINE BIOSCIENCES INC Accounts Receivable, Allowance for Credit Loss
NEUROCRINE BIOSCIENCES INC (NBIX) had Accounts Receivable, Allowance for Credit Loss of $0 as of 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Balance Sheet › Assets
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2026-02-11
- 2025-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2024-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
| Period end | Accounts Receivable, Allowance for Credit Loss |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-11 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |